Entera Bio (NASDAQ:ENTX) Shares Up 10.8% - What's Next?

Key Points

• Entera Bio's stock rose by 10.8% during mid-day trading, reaching as high as $2.35, following a significant increase in trading volume of over 10,000% compared to its average daily volume.
• The company reported quarterly earnings of (-0.06) earnings per share (EPS), surpassing analysts' expectations, with a negative return on equity of 95.10% and a revenue of $0.04 million.
• Institutional investors have shown increasing interest in Entera Bio, with firms like HighTower Advisors boosting their stake by 53.3% in the first quarter.

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report)'s share price was up 10.8% on Monday . The stock traded as high as $2.35 and last traded at $2.06. Approximately 4,272,735 shares traded hands during trading, an increase of 10,648% from the average daily volume of 39,755 shares. The stock had previously closed at $1.86.

Entera Bio Stock Up 0.3%

The firm has a market capitalization of $87.95 million, a price-to-earnings ratio of -7.44 and a beta of 1.46. The stock has a 50 day moving average of $1.95 and a 200 day moving average of $2.02.

Entera Bio (NASDAQ:ENTX - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Entera Bio had a negative net margin of 4,525.11% and a negative return on equity of 95.10%. The business had revenue of $0.04 million during the quarter. Analysts predict that Entera Bio Ltd. will post -0.28 earnings per share for the current year.

Hedge Funds Weigh In On Entera Bio

Several institutional investors and hedge funds have recently modified their holdings of ENTX. Knoll Capital Management LLC grew its holdings in shares of Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company's stock valued at $12,470,000 after acquiring an additional 2,000,000 shares in the last quarter. Northern Trust Corp bought a new stake in Entera Bio in the fourth quarter worth $450,000. Bessemer Group Inc. bought a new stake in Entera Bio in the second quarter worth $268,000. Parkman Healthcare Partners LLC boosted its holdings in Entera Bio by 6.3% in the first quarter. Parkman Healthcare Partners LLC now owns 439,632 shares of the company's stock worth $747,000 after purchasing an additional 25,900 shares in the last quarter. Finally, HighTower Advisors LLC boosted its holdings in Entera Bio by 53.3% in the first quarter. HighTower Advisors LLC now owns 18,140 shares of the company's stock worth $31,000 after purchasing an additional 6,310 shares in the last quarter. 14.11% of the stock is currently owned by hedge funds and other institutional investors.

Entera Bio Company Profile

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.